GleamWall
中文EN

KLRS Kalaris Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1754068 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY21.8%
TTM EPS YoY90.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-97.2%
ROA-51.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets46.7%
Debt / equity0.00x
Current ratio10.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$8.34M$9.02M$7.57M$7.16M$9.13M$8.44M$6.03M-$28.85M
SG&A expense$3.47M$3.37M$4.26M$3.64M$3.62M$3.82M$4.32M$3.28M
Operating income-$11.81M-$12.39M-$11.83M-$10.80M-$12.74M-$12.26M-$10.35M-$7.13M
Interest expense$0$0$0$0$0$0$1.44M$1.31M
Income tax———————$0
Net income-$11.03M-$11.52M-$10.86M-$10.00M-$11.89M-$11.35M-$10.20M-$22.03M
EBITDA-$11.80M-$12.38M-$11.82M-$10.79M————
EPS (basic)-0.46-0.48-0.46—-0.64-0.61-2.52—
EPS (diluted)-0.46-0.48-0.46—-0.64-0.61-2.52—
Weighted avg. shares (diluted)23.80M23.80M23.72M—18.70M18.70M4.05M—
Balance sheet
Cash & equivalents$47.38M$43.17M$34.43M$98.05M$42.39M$88.43M$100.97M$1.64M
Short-term investments$35.47M$50.37M$62.79M$19.93M$34.61M——$0
Current assets$85.18M$95.92M$98.47M$118.81M$78.18M$91.65M$102.18M$2.61M
Total assets$89.00M$99.54M$109.81M$121.74M$81.17M$92.84M$103.09M$6.16M
Current liabilities$8.51M$8.74M$8.08M$9.71M$6.07M$7.65M$7.14M$24.70M
Total liabilities$41.60M$41.87M$41.25M$42.92M$39.31M$39.73M$39.22M$56.78M
Shareholders' equity$47.40M$57.67M$68.56M$78.81M$41.87M$53.12M$63.87M-$96.62M
Shares outstanding23.80M23.80M22.99M22.90M18.70M18.70M18.70M1.36M
Cash flow statement
Operating cash flow-$10.55M-$11.05M-$11.58M-$7.06M-$11.33M-$12.54M-$7.44M-$7.85M
Capital expenditure———$17,000————
Free cash flow———-$7.07M————
Investing cash flow$14.84M$20.17M-$50.35M$14.98M———$5.00M
Financing cash flow-$75,000-$377,000-$1.70M$47.74M$0$0$107.27M$7.58M
Depreciation & amortization$10,000$10,000$10,000$10,000————
Stock-based compensation$752,000$644,000$580,000$333,000$638,000$591,000$374,000$280,000

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.